natgillin/translations-raw huggingface dataset:
Stevens- Johnsons syndrom (sjælden alvorlig hudreaktion), angioneurotisk ødem (hævelse af ansigt, læber, mund, tunge eller svælg, som kan forårsage synke - og åndedrætsbesvær), alvorlige forstoppelse, nedsat effektivitet af tyndtarm og nældefeber (urticaria).
Stevens-Johnson syndrome (rare severe skin reaction), angioedema (swelling of the face, lips, mouth, tongue or throat which may cause difficulty in swallowing or breathing), serious constipation, small bowel not working properly (sub-ileus), and urticaria (hives).
Efter markedføring er følgende bivirkninger set (frekvens ikke kendt):
During post-marketing experience the following side effects have been reported (frequency not known):
Hvis nogle af bivirkningerne bliver alvorlige, eller hvis De oplever nogen form for bivirkninger, som ikke er nævnt i denne indlægsseddel, bør De kontakte lægen eller apoteket.
If any of the side effects gets serious, or if you experience any side effects not listed in this leaflet, please tell your doctor or pharmacist.
Sprøg på apoteket hvordan De skal aflevere medicinrester.
Medicines should not be disposed of via wastewater or house hold waste.
EMEND indeholder Det aktive indholdsstof er aprepitant.
What EMEND contains The active substance is aprepitant.
Saccharose, mikrokrystallinsk cellulose (E460), hydroxypropylcellulose (E463), natriumlaurilsulfat, gelatine, titandioxid (E171), shellak, kaliumhydroxid, sort jernoxid (E172), rød jernoxid (E172) og gul jernoxid (E172).
The other ingredients are: sucrose, microcrystalline cellulose (E 460), hydroxypropyl cellulose (E 463), sodium laurilsulfate, gelatin, titanium dioxide (E 171), shellac, potassium hydroxide, black iron oxide (E 172), red iron oxide (E 172) and yellow iron oxide (E 172).
125 mg kapsel
What EMEND looks like and contents of the pack The 125 mg hard capsule is opaque with a white body and pink cap with “462” and “125 mg” printed radially in black ink on the body.
Ikke alle pakningsstørrelser er nødvendigvis markedsført.
86 EMEND 125 mg hard capsules are supplied in the following pack sizes: • Aluminum blister containing one 125 mg capsule • 5 Aluminum blisters each containing one 125 mg capsule
87 Eλλάδα BIANEΞ Α. Ε Τηλ: +3 0210 80091 11 Mailbox@ vianex. gr
Eλλάδα BIANEΞ Α.Ε Τηλ: +3 0210 80091 11 Mailbox@vianex.gr.
Tel.: +421 2 58282010 md_ sk@ merck. com
Tel.: +421 2 58282010 msd_sk@merck.com
EMEND 125 mg hårde kapsler aprepitant
EMEND 125 mg hard capsules EMEND 80 mg hard capsules aprepitant
De kan få brug for at læse den igen. • Spørg lægen eller på apoteket, hvis der er mere, De vil vide. • Lægen har ordineret EMENDtil Dem personligt..
You may need to read it again. • If you have any further questions, ask your doctor or pharmacist. • This medicine has been prescribed for you.
Det kan være skadeligt for andre, selvom de har de samme symptomer, som De har. • Tal med lægen eller apoteket hvis en bivirkning bliver værre, eller De får bivirkninger, som ikke er nævnt her.
It may harm them, even if their symptoms are the same as yours. • If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.
EMEND bruges i kombination med anden medicin til at forebygge kvalme og opkastning i forbindelse med kemoterapibehandling( behandling af kræft).
EMEND is used in combination with other medicines to prevent nausea and vomiting caused by chemotherapy (cancer treatment).
89 Brug af EMEND sammen med mad og drikke EMEND kan tages med eller uden mad.
Taking EMEND with food and drink EMEND can be taken with or without food.
Graviditet og amning De bør ikke tage EMEND under graviditet, medmindre det er klart nødvendigt.
89 Pregnancy and breast-feeding You should not use EMEND during pregnancy unless clearly necessary.
Hvis Deres læge har informeret Dem om, at De er overfølsom over for visse sukkerarter, bør De kontakte lægen før De anvender dette lægemiddel.
If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.
90 Almidelig bivirkning (forekommer hos 1- 10 ud af 100 brugere) Ikke almindelig (forekommer hos 1- 10 ud af 1000 brugere) Sjælden (forekommer hos 1- 10 ud af 10. 000 brugere) Meget sjælden (forekommer hos færre end 1 ud af 10. 000 brugere) Ikke kendt (frekvens kan ikke estimeres ud fra forhåndenværende data).
The frequency of possible side effects listed below is defined using the following convention: very common (affects more than 1 user in 10) common (affects 1 to 10 users in 100) uncommon (affects 1 to 10 users in 1,000) rare (affects 1 to 10 users in 10,000) very rare (affects less than 1 user in 10,000) not known (frequency cannot be estimated from the available data).
Opstød, forstoppelse, diarré, svimmelhed, kraftløshed, træthed, hovedpine, hikke, fordøjelsesbesvær, appetitløshed og forhøjede levertal.
90 Common side effects are: burping, constipation, diarrhoea, dizziness, weakness, tiredness, headache, hiccups, indigestion, loss of appetite, and increased liver enzymes.
Unormale drømme, akne, angst, bakteriel infektion, oppustethed, blod i urinen, brystgener, hoste, koncentrationsbesvær, forvirring, mundtørhed, tåreflåd, øjenkløe, opstemthed, (ekstrem lykkefølelse), øget svedtendens, udtalt tørst, feber med øget risiko for infektion, svampeinfektion, halsbrand, forhøjet blodsukker, hedeture, øget smertefuld og sviende fornemmelse ved vandladning, betændelse i tyndtarmen og tyktarmen, kløe, lavt indhold af natrium i blodet, nedsat antal røde blodlegemer, irritation i halsen, muskelkramper eller muskelsmerter, kvalme, fedtet hud, luftafgang fra tarmen, røde blodlegener i urinen, udslæt, ansigtsrødmen, ringen for ørerne, lysfølsomhed, svær forstoppelse, langsom hjerterytme, nysen, ondt i halsen, sår i munden eller på huden, mavepine, mavesår, hævelse, smagsforstyrrelser, irritation i halsen, opkastning og vægtøgning eller vægttab.
Uncommon side effects are: abnormal dreaming, acne, anxiousness, bacterial infection, bloating, blood in the urine, chest discomfort, cough, difficulty thinking, disorientation, dry mouth, eye discharge and itching, euphoria (feeling of extreme happiness), excessive sweating, excessive thirst, fever with increased risk of infection, fungal infection, heartburn, high sugar levels in the blood, hot flush, increased painful or burning urination, inflammation of the small intestine and colon, itching, low sodium levels in the blood, lowering of red blood cells, mucus in back of throat, muscle cramp or pain, nausea, oily skin, passing wind, presence of red blood cells in the urine, rash, reddening of the face, ringing in the ear, sensitivity to light, severe constipation, slow heartbeat, sneezing, sore throat, sores in mouth, sores on skin, stomach pain, stomach ulcer, swelling, taste disturbance, throat irritation, vomiting, and weight gain or loss.
125 mg kapslen indeholder også rød jernoxid (E172) og gul jernoxid (E172).
The other ingredients are: sucrose, microcrystalline cellulose (E 460), hydroxypropyl cellulose (E 463), sodium laurilsulfate, gelatin, titanium dioxide (E 171), shellac, potassium hydroxide, and black iron oxide (E 172); the 125 mg hard capsule also contains red iron oxide (E 172) and yellow iron oxide (E 172).
91 EMENDs udseende og pakningsstørrelser 125 mg kapslen er ugennemsigtig med hvid kerne og lyserød kappe med "462" og "125 mg" præget med sort blæk på kapslen.
91 What EMEND looks like and contents of the pack The 125 mg hard capsule is opaque with a white body and pink cap with “462” and “125 mg” printed radially in black ink on the body.
80 mg kapsler.
The 80 mg hard capsule is opaque with a white cap and body with “461” and “80 mg” printed radially in black ink on the body.
Ikke alle pakningsstørrelser er nødvendigvis markedsført
EMEND 125 mg and 80 mg hard capsules are supplied in the following pack sizes: • 3-day treatment pack containing one 125 mg capsule and two 80 mg capsules
.
V.
Fremstiller Merck Sharp & Dohme B. V Waarderweg 39, Postbus 581 NL- 2003 PC Haarlem Holland
Waarderweg 39, Postbus 581 NL-2003 PC Haarlem The Netherlands
92 Eλλάδα BIANEΞ Α. Ε Τηλ: +3 0210 80091 11 Mailbox@ vianex. gr
92 Eλλάδα BIANEΞ Α.Ε Τηλ: +3 0210 80091 11 Mailbox@vianex.gr
Tel: +371 67364 224 msd_ lv@ merck. com
Latvija SIA “Merck Sharp & Dohme Latvija” Tel: +371 67364 224 msd_lv@merck.com
Hvad er EMSELEX?
What is EMSELEX?
EMSELEX er hvide (7, 5 mg) eller let ferskenfarvede (15 mg) runde depottabletter, der indeholder det aktive stof darifenacin (en depottablet betyder, at darifenacin afgives langsomt fra tabletten i løbet af nogle få timer).
EMSELEX are white (7.5 mg) or light peach (15 mg) round prolonged-release tablets that contain the active substance darifenacin (prolonged-release means that darifenacin is released slowly from the tablet over a few hours).
Hvad anvendes EMSELEX til?
What is EMSELEX used for?
EMSELEX anvendes hos voksne patienter med overaktiv blære- syndrom til behandling af den urge - inkontinens (pludselig manglende kontrol over vandladningen), øgede vandladningshyppighed og øgede pludselige vandladningstrang, som er knyttet til syndromet.
EMSELEX is used in adult patients with overactive bladder syndrome to treat the urge incontinence (sudden lack of control over urination), increased urinary frequency (need to urinate frequently) and urgency (sudden urge to pass urine) that are associated with the syndrome.
Hvordan anvendes EMSELEX?
How is EMSELEX used?
Den anbefalede startdosering er 7, 5 mg en gang dagligt.
The recommended starting dose is 7.5 mg once daily.
Hos patienter, der har større behov for afhjælpning af symptomerne, kan dosis øges til 15 mg.
For those patients requiring greater symptom relief, the dose may be increased to 15 mg.
Tabletterne kan tages med eller uden samtidig fødeindtagelse og skal synkes hele med lidt væske, men må ikke tygges, deles eller knuses.
The tablets can be taken with or without food, and should be swallowed whole, with some liquid, and not chewed, divided or crushed.
Hvordan virker EMSELEX?
How does EMSELEX work?
Det aktive stof i EMSELEX, darifenacin, er et antikolinergt middel.
The active substance in EMSELEX, darifenacin, is an anticholinergic medicine.
Det blokerer en receptor i kroppen, den muskarine M3- receptor, og i blæren bevirker dette afslappelse af de muskler, der presser urinen ud af blæren.
It blocks a receptor in the body, the muscarinic M3 receptor, and in the bladder, this causes the muscles which pushes urine out of the bladder to relax.
Dette medfører, at blærekapaciteten øges, at blæremusklernes sammentrækning ændrer karakter, og at der bliver færre blæresammentrækninger.
This leads to an increased capacity of the bladder, to changes in the way the bladder contracts, and to less bladder contractions.
Derved medvirker EMSELEX til at forebygge ufrivillig vandladning.
This helps EMSELEX to prevent unwanted urination.
Hvordan er EMSELEX blevet undersøgt?
How has EMSELEX been studied?
Der er gennemført fire hovedundersøgelser af EMSELEX hos i alt 2 078 mandlige og kvindelige patienter med symptomer på overaktiv blære.
EMSELEX has been studied in four main studies in a total of 2,078 male and female patients with symptoms of overactive bladder.
EMSELEX blev anvendt i forskellige doseringer (fra 3, 75 mg til 30 mg dagligt) og sammenlignet med placebo (virkningsløs behandling) eller med tolterodin (et andet lægemiddel, der anvendes til behandling af denne lidelse).
EMSELEX was used at different dosages (from 3.75 mg to 30 mg daily) and compared with placebo (dummy treatment) or with tolterodine (another medicine used in this condition).
Hovedmålet var behandlingens virkning på det ugentlige antal episoder med ufrivillig vandladning.
The main measure was the effect of the treatment on the number of incontinence episodes per week.
Hvilken fordel viser undersøgelserne, at der er ved EMSELEX?
What benefit has EMSELEX shown during the studies?
Når resultaterne af alle fire undersøgelser lægges sammen, var EMSELEX mere effektivt end placebo til at mindske antallet af episoder med ufrivillig vandladning.
Patients receiving EMSELEX 7.5 mg or 15 mg had
De patienter, der fik EMSELEX 7, 5 mg 7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
(44- 20) 74 18 84 00 Fax (44- 20) 74 18 84 16 E- mail: mail@ emea. eu. int http: // www. emea. eu. int EMEA 2006 Reproduction and/ or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged eller 15 mg havde henholdsvis 10, 6 (68%) og 12, 5 (77%) færre episoder med ufrivillig vandladning pr. uge, mens de patienter, der fik placebo, havde henholdsvis 7 og 7, 5 (54 og 58%) færre episoder pr. uge.
(44-20) 74 18 84 00 Fax (44-20) 74 18 84 16 E-mail: mail@emea. eu. int http: / /www. emea. eu. int  EMEA 2006 Reproduction and/ or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged 10.6 (68%) or 12.5 (77%) less episodes of incontinence per week, respectively, when patients receiving placebo had 7 or 7.5 (54 or 58%) less episodes per week.
Hvilken risiko er der forbundet med EMSELEX?
What is the risk associated with EMSELEX?
De hyppigste bivirkninger (som ses hos flere end 1 ud af 10 patienter) er mundtørhed og forstoppelse.
The most common side effects (seen in more than 1 patient in 10) are dry mouth and constipation.
Den fuldstændige liste over de indberettede bivirkninger ved EMSELEX fremgår af indlægssedlen.
For the full list of all side effects reported with EMSELEX, please see the Package Leaflet.
EMSELEX må ikke anvendes til patienter, der kan være overfølsomme (allergiske) over for darifenacin eller andre af indholdsstofferne, eller hos patienter med: • Urinretention (manglende evne til at lade vandet) • Ventrikelretention (manglende fuldstændig tømning af mavesækken) • Ukontrolleret snævervinklet grøn stær (for højt væsketryk i øjet, selv når det behandles) • Myasthenia gravis (en nervesygdom, som medfører muskelsvækkelse) • Svært nedsat leverfunktion • Svær colitis ulcerosa (en alvorlig tyktarmsbetændelse, der medfører sårdannelse og blødning) • Toksisk megacolon (en meget alvorlig komplikation til tyktarmsbetændelse – se ovenfor) EMSELEX bør ikke gives samtidig med lægemidler som cyklosporin (hos transplantationspatienter), verapamil (en hjertemedicin), proteasehæmmere (lægemidler som ritonavir, der anvendes hos AIDS - patienter) eller ketoconazol og itraconazol (der anvendes til behandling af svampeinfektioner).
EMSELEX should not be used in people who may be hypersensitive (allergic) to darifenacin or any of the other ingredients, and in patients with: • Urinary retention (difficulty in passing urine) • Gastric retention (when the stomach doesn ’ t empty properly) • Uncontrolled narrow-angle glaucoma (increased eye pressure even with treatment) • Myasthenia gravis (a disease of the nerves causing muscle weakness). • Severe hepatic impairment (severe liver disease). • Severe ulcerative colitis (severe inflammation of the large intestine causing ulceration and bleeding) • Toxic megacolon (a very serious complication of colitis – see above) EMSELEX should not be given to patients at the same time as medicine such cyclosporine (in transplant patients), verapamil (a heart medicine), protease inhibitors (medicines such as ritonavir, used in AIDS patients) or ketoconazole and itraconazole (used to treat fungal infections).
Hvorfor er EMSELEX blevet godkendt?
Why has EMSELEX been approved?
Udvalget for Humanmedicinske Lægemidler (CHMP) konkluderede, at EMSELEX udviste en virkning, der svarer til virkningen af andre antikolinerge midler, som bruges ved overaktiv blære - syndrom.
The Committee for Medicinal Products for Human Use (CHMP) concluded that EMSELEX showed an effectiveness similar to that of other anticholinergic medicines used in overactive bladder syndrome.
Udvalget konkluderede, at fordelene ved EMSELEX er større end risiciene ved symptomatisk (lindrende) behandling af urge- inkontinens og/ eller øget vandladningshyppighed og - trang, således som dette kan forekomme hos patienter med overaktiv blære- syndrom.
They decided that EMSELEX’ s benefits are greater than its risks for the symptomatic treatment of urge incontinence and/ or increased urinary frequency and urgency as may occur in patients with overactive bladder syndrome.
Udvalget anbefalede udstedelse af markedsføringstilladelse for EMSELEX.
They recommended that EMSELEX be given marketing authorisation.
Andre oplysninger om EMSELEX:
Other information about EMSELEX:
Europa- Kommissionen udstedte en markedsføringstilladelse med gyldighed i hele Den Europæiske Union for EMSELEX til Novartis Europharm Limited den 22. oktober 2004.
The European Commission granted a marketing authorisation valid throughout the European Union for EMSELEX to Novartis Europharm Limited on 22 October 2004.
Den europæiske offentlige vurderingsrapport (EPAR) for EMSELEX kan ses i sin helhed her.
The full EPAR for EMSELEX is available here.
Dette sammendrag blev sidst ajourført i marts 2006
This summary was last updated in 03-2006.
EU- nummer EU/ 1/ 04/ 294/ 001 EU/ 1/ 04/ 294/ 002 EU/ 1/ 04/ 294/ 003 EU/ 1/ 04/ 294/ 004 EU/ 1/ 04/ 294/ 005 EU/ 1/ 04/ 294/ 006 EU/ 1/ 04/ 294/ 007 EU/ 1/ 04/ 294/ 008 EU/ 1/ 04/ 294/ 009 EU/ 1/ 04/ 294/ 010 EU/ 1/ 04/ 294/ 011 EU/ 1/ 04/ 294/ 012 EU/ 1/ 04/ 294/ 013
EU/ 1/ 04/ 294/ 001 EU/ 1/ 04/ 294/ 002 EU/ 1/ 04/ 294/ 003 EU/ 1/ 04/ 294/ 004 EU/ 1/ 04/ 294/ 005 EU/ 1/ 04/ 294/ 006 EU/ 1/ 04/ 294/ 007 EU/ 1/ 04/ 294/ 008 EU/ 1/ 04/ 294/ 009 EU/ 1/ 04/ 294/ 010 EU/ 1/ 04/ 294/ 011 EU/ 1/ 04/ 294/ 012 EU/ 1/ 04/ 294/ 013
Særnavn Emselex Emselex Emselex Emselex Emselex Emselex Emselex Emselex Emselex Emselex Emselex Emselex Emselex
Emselex Emselex Emselex Emselex Emselex Emselex Emselex Emselex Emselex Emselex Emselex Emselex Emselex
Styrke 7, 5 mg 7, 5 mg 7, 5 mg 7, 5 mg 7, 5 mg 7, 5 mg 15 mg 15 mg 15 mg 15 mg 15 mg 15 mg 7, 5 mg
7.5 mg 7.5 mg 7.5 mg 7.5 mg 7.5 mg 7.5 mg 15 mg 15 mg 15 mg 15 mg 15 mg 15 mg 7.5 mg
Lægemiddelform Depottablet Depottablet Depottablet Depottablet Depottablet Depottablet Depottablet Depottablet Depottablet Depottablet Depottablet Depottablet Depottablet
Prolonged release tablet Prolonged release tablet Prolonged release tablet Prolonged release tablet Prolonged release tablet Prolonged release tablet Prolonged release tablet Prolonged release tablet Prolonged release tablet Prolonged release tablet Prolonged release tablet Prolonged release tablet Prolonged release tablet
Indgivelsesvej Oral anvendelse Oral anvendelse Oral anvendelse Oral anvendelse Oral anvendelse Oral anvendelse Oral anvendelse Oral anvendelse Oral anvendelse Oral anvendelse Oral anvendelse Oral anvendelse Oral anvendelse
Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use
Emballage blister (PVC/ CTFE/ ALU) blister (PVC/ CTFE/ ALU) blister (PVC/ CTFE/ ALU) blister (PVC/ CTFE/ ALU) blister (PVC/ CTFE/ ALU) blister (PVC/ CTFE/ ALU) blister (PVC/ CTFE/ ALU) blister (PVC/ CTFE/ ALU) blister (PVC/ CTFE/ ALU) Blister (PVC/ CTFE/ ALU) blister (PVC/ CTFE/ ALU) blister (PVC/ CTFE/ ALU) blister (PVC/ CTFE/ ALU)
blister (PVC/ CTFE/ alu) blister (PVC/ CTFE/ alu) blister (PVC/ CTFE/ alu) blister (PVC/ CTFE/ alu) blister (PVC/ CTFE/ alu) blister (PVC/ CTFE/ alu) blister (PVC/ CTFE/ alu) blister (PVC/ CTFE/ alu) blister (PVC/ CTFE/ alu) blister (PVC/ CTFE/ alu) blister (PVC/ CTFE/ alu) blister (PVC/ CTFE/ alu) blister (PVC/ CTFE/ alu)
Pakningsstørrelse 7 tabletter 14 tabletter 28 tabletter 49 tabletter 56 tabletter 98 tabletter 7 tabletter 14 tabletter 28 tabletter 49 tabletter 56 tabletter 98 tabletter 14x10 tabletter (multipakning)
7 tablets 14 tablets 28 tablets 49 tablets 56 tablets 98 tablets 7 tablets 14 tablets 28 tablets 49 tablets 56 tablets 98 tablets 14 x 10 tablets (multipack)
blister (PVC/ CTFE/ ALU)
blister (PVC/ CTFE/ alu)
14x10 tabletter (multipakning)
14 x 10 tablets (multipack)
EU/ 1/ 04/ 294/ 015 EU/ 1/ 04/ 294/ 016 EU/ 1/ 04/ 294/ 017 EU/ 1/ 04/ 294/ 018 EU/ 1/ 04/ 294/ 019 EU/ 1/ 04/ 294/ 020 EU/ 1/ 04/ 294/ 021 EU/ 1/ 04/ 294/ 022 EU/ 1/ 04/ 294/ 023 EU/ 1/ 04/ 294/ 024 EU/ 1/ 04/ 294/ 025 EU/ 1/ 04/ 294/ 026 EU/ 1/ 04/ 294/ 027
EU/ 1/ 04/ 294/ 015 EU/ 1/ 04/ 294/ 016 EU/ 1/ 04/ 294/ 017 EU/ 1/ 04/ 294/ 018 EU/ 1/ 04/ 294/ 019 EU/ 1/ 04/ 294/ 020 EU/ 1/ 04/ 294/ /021 EU/ 1/ 04/ 294/ 022 EU/ 1/ 04/ 294/ 023 EU/ 1/ 04/ 294/ 024 EU/ 1/ 04/ 294/ 025 EU/ 1/ 04/ 294/ 026 EU/ 1/ 04/ 294/ 027
Emselex Emselex Emselex Emselex Emselex Emselex Emselex Emselex Emselex Emselex Emselex Emselex Emselex
Emselex Emselex Emselex Emselex Emselex Emselex Emselex Emselex Emselex Emselex Emselex Emselex Emselex
7, 5 mg 7, 5 mg 7, 5 mg 7, 5 mg 7, 5 mg 7, 5 mg 15 mg 15 mg 15 mg 15 mg 15 mg 15 mg 7, 5 mg
7.5 mg 7.5 mg 7.5 mg 7.5 mg 7.5 mg 7.5 mg 15 mg 15 mg 15 mg 15 mg 15 mg 15 mg 7.5 mg
Depottablet Depottablet Depottablet Depottablet Depottablet Depottablet Depottablet Depottablet Depottablet Depottablet Depottablet Depottablet Depottablet
Prolonged release tablet Prolonged release tablet Prolonged release tablet Prolonged release tablet Prolonged release tablet Prolonged release tablet Prolonged release tablet Prolonged release tablet Prolonged release tablet Prolonged release tablet Prolonged release tablet Prolonged release tablet Prolonged release tablet
Oral anvendelse Oral anvendelse Oral anvendelse Oral anvendelse Oral anvendelse Oral anvendelse Oral anvendelse Oral anvendelse Oral anvendelse Oral anvendelse Oral anvendelse Oral anvendelse Oral anvendelse
Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use
blister (PVC/ PVDC/ ALU) blister (PVC/ PVDC/ ALU) blister (PVC/ PVDC/ ALU) blister (PVC/ PVDC/ ALU) blister (PVC/ PVDC/ ALU) blister (PVC/ PVDC/ ALU) blister (PVC/ PVDC/ ALU) blister (PVC/ PVDC/ ALU) blister (PVC/ PVDC/ ALU) Blister (PVC/ PVDC/ ALU) blister (PVC/ PVDC/ ALU) blister (PVC/ PVDC/ ALU) blister (PVC/ PVDC/ ALU)
blister (PVC/ PVDC/ alu) blister (PVC/ PVDC/ alu) blister (PVC/ PVDC/ alu) blister (PVC/ PVDC/ alu) blister (PVC/ PVDC/ alu) blister (PVC/ PVDC/ alu) blister (PVC/ PVDC/ alu) blister (PVC/ PVDC/ alu) blister (PVC/ PVDC/ alu) blister (PVC/ PVDC/ alu) blister (PVC/ PVDC/ alu) blister (PVC/ PVDC/ alu) blister (PVC/ PVDC/ alu)
7 tabletter 14 tabletter 28 tabletter 49 tabletter 56 tabletter 98 tabletter 7 tabletter 14 tabletter 28 tabletter 49 tabletter 56 tabletter 98 tabletter 14x10 tabletter (multipakning)
7 tablets 14 tablets 28 tablets 49 tablets 56 tablets 98 tablets 7 tablets 14 tablets 28 tablets 49 tablets 56 tablets 98 tablets 14 x 10 tablets (multipack)
blister (PVC/ PVDC/ ALU)
blister (PVC/ PVDC/ alu)
Emselex 7, 5 mg depottabletter
Emselex 7.5 mg prolonged-release tablets
Hver tablet indeholder 7, 5 mg darifenacin (som hydrobromid)
Each tablet contains 7.5 mg of darifenacin (as hydrobromide)
Depottabletter
Prolonged-release tablets
Hvid rund, konveks tablet, præget med ” DF ” på den ene side og ” 7. 5 ” på den modsatte.
White round, convex tablet, debossed with “ DF” on one side and “ 7.5” on the reverse.
Symptomatisk behandling af urgeinkontinens og/ eller øget vandladningsfrekvens og imperiøs vandladning, som kan forekomme hos patienter med overaktiv blæresyndrom.
Symptomatic treatment of urge incontinence and/ or increased urinary frequency and urgency as may occur in patients with overactive bladder syndrome.
Voksne (≥18 år) Den anbefalede startdosering er 7, 5 mg daglig.
Adults (≥ 18 years) The recommended starting dose is 7.5 mg daily.
Emselex bør tages en gang daglig sammen med væske.
Emselex should be taken once daily with liquid.
Tabletterne må ikke tygges, deles eller knuses.
The tablets can be taken with or without food, and must be swallowed whole and not chewed, divided or crushed.
Ældre (≥65 år) Den anbefalede startdosis for ældre er 7, 5 mg daglig.
Elderly patients (≥ 65 years) The recommended starting dose for the elderly is 7.5 mg daily.
5. 2).
For those patients who have an acceptable tolerability profile but require greater symptom relief, the dose may be increased to 15 mg daily, based on individual response (see section 5.2).